6 results about "Targeted Radiotherapy" patented technology

This application discloses a real-time adaptive radiotherapy management system, relating to the field of medical technology. The system includes: a real-time data processing unit for acquiring real-time data of the target object during radiotherapy; an adaptive decision-making unit for determining a target radiotherapy plan matching the current state of the target object from multiple alternative radiotherapy plans based on the real-time data, wherein the multiple alternative radiotherapy plans are associated with different physiological motion phases or anatomical states of the target object; a plan execution sequence splitting unit for parsing and splitting each alternative radiotherapy plan into one or more hardware execution sequences; and an execution scheduling unit for sending at least one hardware execution sequence corresponding to the target radiotherapy plan to the control system of the radiotherapy equipment. This application solves the technical problem that existing adaptive radiotherapy systems, due to their rigid architecture and singular decision-making mode, cannot achieve highly real-time dynamic plan switching during treatment.

This invention discloses a folic acid receptor-targeting compound and its uses, belonging to the field of pharmaceutical technology. The folic acid receptor-targeting compound is a compound of formula (I), its stereoisomer, its crystalline hydrate, its deuterated derivative, its solvate, its prodrug, or a pharmaceutically acceptable salt thereof: [target]-(L x ) s -R x (I), where [target] is a folic acid receptor-binding ligand; R x The chelating group is Ch or the prosthetic group is PG; s is an integer from 1 to 10; L x It contains at least one L 3 and with AA, L 1 L 2 or L 3 Arbitrary combinations are possible. The folic acid receptor-targeting compounds of this invention have low KD values ​​and strong affinity between the ligands and receptors, and can be used as folic acid receptor-targeted radiotherapy agents for imaging, diagnosis, and treatment of folic acid receptor (FR)-expressing tumors or cells.

The present invention relates to compounds of formula (I) that have the potential to be used as metal complexes in radiotherapy. TIFF2024538619000043.tif85132 (wherein A is CO2R 1 , and PO3R 1 and B is selected from the group consisting of COR 2 , and PO3R 2 R 1 , R 2 and R 3 are each independently H and C1 to C 12 alkyl, and each R a is independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN; b are independently selected from the group consisting of H, F, Cl, Br, I, CH3, CH2CH3, CH(CH3)2, OH, OCH3, OCH2CH3, CF3, OCF3, NO2, NH2, and CN, and L is a linker having 1 to 20 atoms in the normal chain), or a pharma- ceutically acceptable salt thereof.

To provide compositions, kits, and methods for the diagnosis and treatment of prostate cancer. [Solution] Compositions, kits and methods for treating and detecting cancer, and more particularly, radiolabeled conjugates used for targeted radiotherapy for cancer patients, are provided herein. The present invention provides, for example, a cancer-targeting compound for treating cancer cells overexpressing PSMA, wherein the compound comprises a radioisotope, a chelating agent and a PSMA-targeting moiety, the PSMA-targeting moiety being linked to the chelating agent.

This invention provides a method, apparatus, and electronic device for determining radiotherapy plans based on nanodosimetry, relating to the field of radiation technology. The method for determining radiotherapy plans based on nanodosimetry includes: obtaining time-varying distribution data of nanodosimetry within a mixed heavy ion beam radiation field using a simulation platform; wherein the mixed heavy ion beam radiation field corresponds to a candidate radiotherapy plan at an ultra-high dose rate for the target patient; the ultra-high dose rate is a dose rate greater than a target threshold; based on the time-varying distribution data of nanodosimetry, obtaining a dose correction factor corresponding to the candidate radiotherapy plan using a cell survival fraction model; and adjusting the candidate radiotherapy plan according to the dose correction factor to obtain the target radiotherapy plan for the target patient. This invention can establish an accurate and reliable biophysical model of a heavy ion ultra-high dose rate radiation field, enabling the determination of precise radiotherapy plans based on this biophysical model.

The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and / or mammalian tissue overexpressing prostate specific membrane antigen ("PSMA") where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M1 is independently at each occurence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.